LifeSci Investor

@Biotech2k1 AI will be very disruptive and will turn the industry upside down. How much of an impact, no one knows for certain. ServiceNow, Salesforce, Oracle, etc. and many more decimated in the last 6 months.

@BehroozNajafi Nope. Silly WS behavior is opportunity for a patient and disciplined investor.

Building my first new Notebook after deleting all my research last week. I am going to start with Tech then Fintech then go back to and do Biotech. I will build a thread for each theme with all my company DD in it. I am building a $SNOW notebook right now. I will use that build a profile of the company. Then I will publish it along with my valuation. I make a thread for each of tech, fintech and biotech an pin them to my highlights. I will take a lot of time, but I have plenty of time in this market.

$TGTX Yet he will probably have the lowest price on the stock 😂. Just a second rate analyst. 14% QoQ growth will get the sales over a Billion for 2026.

@Lucy3370 $Qure Makary can always overrule. I think he will eventually be replaced. We can't risk losing our Biotech innovation leadership to the Chinese (if not already).

$qure my thoughts on Prasad replacement - many concerned Makary will still stand in way of rare disease. Imho if some1 hired who has history of being friendly to rare disease industry he/she wud only take job W/understanding he/she runs the show in their area , not makary

@semodough $TGTX I believe these numbers do not include the SubQ sales. IV alone has the potential to surpass the $925M estimate. With the increased buybacks the outlook is bright. And we haven’t even included Azer-cel and other indications in the model.

$TGTX Cowen model goes out even longer but clearly see #Briumvi Duration /retention continues in coming years with patents thru 2042+. Sub-q - Azer upside catalysts this year

@Biotech2k1 Took advantage of the opportunity and added a decent amount of $LABD. We’ll see of this M&A talk has legs.

Looking to double dip $LABD if we pop more so I have a nice size hedge to carry me through my slashing weighting down to 25%. The FOMO is same as 2021 now. I have other sectors to focus on that are far more attractive. I can cut to my top 5 and take some time off from biotech and focus on Fintech and Tech.

@zipjet $TGTX After repaying the existing facility and doing a $200M increase in buybacks, there will be only $300M left. Not much to do anything strategic or significant. May be an early-stage asset acquisition (low probability), or likely more cushion for future expenses or buy-backs.

$TGTX Why did the company decide to raise $500-750M? They must have something big in mind other than raising the buyback $200M.

@Lucy3370 $TGTX Shout out to you for calling this out a couple of weeks ago. I thought it would make sense too. Yes, no BO until data release for SubQ & Azer-cel programs. If positive, the odds will increase a great deal. If no BO, the sales will rocket up in 2028. Win-win.

$tgtx this was pretty timely. 👇👇👇. Glad to c mgmt increasing stock buyback from $100 mil to $300mil

@MMick1222347 @jacked2thatits @zipjet @EL_Goeffrey $TGTX MW's employment agreement calls for annual grant of restricted shares with a grant date value = to 10X the sum of the prior year's base salary + annual cash bonus in Dec/Jan. In 2024 he received 1M shares. Not sure about 2025. That's roughly ~1/3 of $100M buy-back.

@jacked2thatits @zipjet @EL_Goeffrey With all these buybacks, I have not seen the outstanding share count go down. In fact, I just noticed it went UP from 158.8M to 159.7M some time in the last week or two. Any idea why? They immediately giving out bought back shares as options to employees? $tgtx

$TGTX $300M buyback $262M remaining. FINANCING & CAPITAL STRUCTURE New 5-year $750M senior secured credit facility with Blue Owl Capital Repays existing $250M facility Net new capital raised: $500M (non-dilutive) Option to expand facility by additional $250M Total potential facility size: $1B SHARE REPURCHASE PROGRAM Increased buyback authorization from $100M to $300M Already repurchased $38M of stock Average repurchase price: $28.98 per share Signals confidence in valuation and willingness to deploy capital USE OF CAPITAL Share repurchases Business development / acquisitions Operational initiatives Supported by a cash-flow positive business MANAGEMENT TAKEAWAYS CEO Michael Weiss highlighted: Improved scale and terms vs prior facility Ability to fund growth of BRIUMVI and pipeline Buyback reflects confidence in long-term value Blue Owl noted: Strong commercial execution of BRIUMVI Disciplined growth strategy BRIUMVI OVERVIEW Anti-CD20 monoclonal antibody for relapsing multiple sclerosis (RMS) Glycoengineered for efficient B-cell depletion Approved in U.S. and multiple international markets KEY SAFETY POINTS Infusion reactions (~48%) Infection rate ~56% (serious ~5%) Risk of HBV reactivation Risk of PML (rare but severe brain infection) Other risks: liver injury, reduced immunoglobulins, fetal risk INVESTOR TAKEAWAY Large non-dilutive financing strengthens balance sheet Significant expansion of buybacks suggests management sees undervaluation Provides flexibility for growth, M&A, and pipeline investment Reinforces confidence in BRIUMVI-driven cash flow

@peter_mantas $qure Am I mistaken? Isn’t leucovorin a variation of vitamin B9? In high dose it has shown some limited effectiveness in forms of autism (verbal improvement) but not in overall condition.

I had this piece ready this weekend but with the approval of leucovorin and other recent developments, this has to go out today. It has also been confirmed that Prasad wasn't in attendance at the Type A meeting. $QURE 👇 Makary now feeling the heat. botn.bio/p/the-prasad-s…

@Lucy3370 $TGTX Have mentioned this before. SP is insanely undervalued as sales have gone up. Having said that, they've missed the earnings est. repeatedly, expenses have gone up ($450M in 26+millions in RSUs to the Mgmt). Plus slow SubQ delivery. MW shows little concern for SH & SP.

$xbi up 50% last year & $tgtx down 25% in same time frame. In my 25 yrs investing in #biotechs I’ve rarely seen such a disconnect with how well a company is doing vs the general index

$IOVA 131M shares short (~36%) with 8-15 days to cover. With so many potentially positive catalysts coming up it is a very high risk/low reward position for the shorts.

@Lucy3370 $TGTX Need to improve the earnings. Sales are going up but so is the spending. Buy backs are not helpful if a portion goes back out in RSUs & options. I need to understand more about the $100M SubQ expense. They were late (misjudged the value) on SubQ. Still, way undervalued.

$tgtx 1. Great 2025✅ 2. Strong 2026 projected✅ 3. Azer-cel ph1 data soon✅ 4. Combined 1/2 dose data soon ✅ 5. SubQ enroll almost done✅ 6. SubQ data EOY✅ 7. Stock buyback✅ 8. New B study for other indications soon✅ 9. stock near 52 wk low✅ Very bizarre -make it make sense

$TGTX the kind of stock I want to own while markets melt due to the geopolitical situation. Profitable, solid growth and demand not impacted by anything that is going on.

@ngyojiw @semodough BTK

@BehroozNajafi @semodough Is rubbish Fene even anti-cd20?

$TGTX 3 days ago I honestly thought Alec was turning the corner on $TGTX - but after today’s note & what he thinks on Fenebrutinib- imho no he has not 🤷‍♂️TG Therapeutics Fenebrutinib hits on efficacy, some safety debates; BTKis enter the MS fold in 2026

@OzzieChambers $TGTX Don’t forget the liver enzyme elevation and rare occurrence of Hy’s law which require constant monitoring.

$TGTX Genetech's fenebrutinib one relapse every 17 years in newly published studies plus deaths versus Briumvi with one relapse occurring every 50 years of patient treatment. 🤔

@unnatural78 $TGTX Most of the pre/after-market trades are exaggerated and manipulated.

Pre market noobs selling. lol. Sucks to be you. $TGTX

@semodough $TGTX I think YoY growth is close to 40+% for 2026. Sales are ramping up very nicely. I hope we get a good earning number this week and no surprises (unexpected spending or more RSUs and share handouts).

$TGTX JP survey TGTX’s Briumvi (IV) is expected to see another 18% y/y growth in 2026. $TGTX guided. SubQ penetration is expected to grow over time reaching ~45% by 2030. Ultimately,continue to see TG’s SubQ play as next major leg up for the story. • Briumvi appears to be the IV of choice given the erosion expected in Ocrevus (IV).

$ARDX 7.7M shares traded already. BO traders are leaving since there was no mention of any strategic alternatives (or Zydus) on the call. Co. is worth more alone with MC close to 2X 2026 sales and sales growing nicely. HCW raised its PT to $18 from $10. BTIG at $17.